

[Open Peer Review on Qeios](#)

Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine

National Cancer Institute

Source

National Cancer Institute. *Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine*. NCI Thesaurus. Code C70674.

A peptide vaccine preparation, containing recombinant human epidermal growth factor (rEGF) linked to the Neisseria meningitidis-derived recombinant immunogenic carrier protein P64k (rP64k) and mixed with the immunoadjuvant Montanide ISA 51, with potential active immunotherapy activity. Recombinant human EGF-rP64K/Montanide ISA 51 vaccine may trigger a humoral immune response against vaccine rEGF and rP64K and, so, against endogenous EGF. Antibody-mediated inhibition of endogenous EGF binding to its receptor, epithelial growth factor receptor (EGFR), may result in the inhibition of tumor cell proliferation.